Esteban Masuda - Rigel Pharmaceuticals Senior Vice President - Research
| RIGL Stock | USD 18.86 0.15 0.79% |
President
Mr. Esteban Masuda, Ph.D., is Senior Vice President Research of the company. He was appointed Senior Vice President, Research in September 2016. Before being named to that position, Dr. Masuda held the title of Senior Vice President, Immunology since 2013. He joined Rigel as a scientist in 1998. He has worked on and led numerous drug discovery projects in inflammatory and allergic diseases, and served as the first project leader of the program that led to the discovery of fostamatinib. His work has resulted in moving several product candidates into clinical development establishing various corporate partnerships producing 57 publications and issuing 49 U.S. patents. Prior to joining Rigel, Dr. Masuda spent seven years at DNAX Research Institute of Molecular and Cellular Biology in cytokine biology. He received a B.S. in biochemistry from University of California, Riverside and a Ph.D. in molecular genetics from Hiroshima University, Japan. since 2016.
| Age | 62 |
| Tenure | 8 years |
| Professional Marks | Ph.D |
| Address | 611 Gateway Blvd, South San Francisco, CA, United States, 94080 |
| Phone | 650 624 1100 |
| Web | https://www.rigel.com |
Rigel Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0461 % which means that it generated a profit of $0.0461 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (6.9905) %, meaning that it created substantial loss on money invested by shareholders. Rigel Pharmaceuticals' management efficiency ratios could be used to measure how well Rigel Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is expected to rise to 0.92 this year, although the value of Return On Tangible Assets will most likely fall to (0.25). At this time, Rigel Pharmaceuticals' Fixed Asset Turnover is quite stable compared to the past year. Asset Turnover is expected to rise to 1.05 this year, although the value of Other Current Assets will most likely fall to about 4.3 M.Similar Executives
| Found 7 records | PRESIDENT Age | ||
| Jeffrey Stein | Cidara Therapeutics | 69 | |
| Laura Navalta | Cidara Therapeutics | ||
| Robert Lisicki | Zura Bio Limited | 57 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Les Tari | Cidara Therapeutics | N/A | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
Management Performance
| Return On Equity | -6.99 | ||||
| Return On Asset | 0.0461 |
Rigel Pharmaceuticals Leadership Team
Elected by the shareholders, the Rigel Pharmaceuticals' board of directors comprises two types of representatives: Rigel Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rigel. The board's role is to monitor Rigel Pharmaceuticals' management team and ensure that shareholders' interests are well served. Rigel Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rigel Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Esteban Masuda, Senior Vice President - Research | ||
| Joseph Lasaga, Senior Vice President - Business Development and Alliance Management | ||
| Raymond JD, General VP | ||
| Tarek Sallam, Vice Marketing | ||
| David Santos, Executive Officer | ||
| Dean CPA, Executive CFO | ||
| Julie Patel, Senior Resources | ||
| Lisa MD, Executive Officer | ||
| Wolfgang MD, Ex Officer | ||
| Raul Rodriguez, CEO and President Director and Member of Fin. Committee |
Rigel Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Rigel Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -6.99 | ||||
| Return On Asset | 0.0461 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 343.14 M | ||||
| Shares Outstanding | 17.61 M | ||||
| Shares Owned By Insiders | 2.18 % | ||||
| Shares Owned By Institutions | 68.05 % | ||||
| Number Of Shares Shorted | 470.93 K | ||||
| Price To Earning | (5.63) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.48) | Earnings Share 0.26 | Revenue Per Share 8.979 | Quarterly Revenue Growth 0.966 | Return On Assets 0.0461 |
The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.